- Home
- PNF vs SCLX Comparison
PNF vs SCLX Comparison
Compare PNF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNF
- SCLX
- Stock Information
- Founded
- PNF 2001
- SCLX 2011
- Country
- PNF United States
- SCLX United States
- Employees
- PNF N/A
- SCLX N/A
- Industry
- PNF Finance Companies
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- PNF Finance
- SCLX Health Care
- Exchange
- PNF Nasdaq
- SCLX Nasdaq
- Market Cap
- PNF 59.6M
- SCLX 51.3M
- IPO Year
- PNF N/A
- SCLX N/A
- Fundamental
- Price
- PNF $7.51
- SCLX $0.30
- Analyst Decision
- PNF
- SCLX Strong Buy
- Analyst Count
- PNF 0
- SCLX 4
- Target Price
- PNF N/A
- SCLX $13.00
- AVG Volume (30 Days)
- PNF 29.1K
- SCLX 1.2M
- Earning Date
- PNF 01-01-0001
- SCLX 05-12-2025
- Dividend Yield
- PNF 5.17%
- SCLX N/A
- EPS Growth
- PNF N/A
- SCLX N/A
- EPS
- PNF N/A
- SCLX N/A
- Revenue
- PNF N/A
- SCLX $56,590,000.00
- Revenue This Year
- PNF N/A
- SCLX $115.30
- Revenue Next Year
- PNF N/A
- SCLX $73.33
- P/E Ratio
- PNF N/A
- SCLX N/A
- Revenue Growth
- PNF N/A
- SCLX 21.07
- 52 Week Low
- PNF $6.37
- SCLX $0.21
- 52 Week High
- PNF $9.06
- SCLX $2.30
- Technical
- Relative Strength Index (RSI)
- PNF 42.37
- SCLX 51.34
- Support Level
- PNF $7.44
- SCLX $0.22
- Resistance Level
- PNF $7.76
- SCLX $0.29
- Average True Range (ATR)
- PNF 0.09
- SCLX 0.04
- MACD
- PNF -0.01
- SCLX 0.00
- Stochastic Oscillator
- PNF 30.53
- SCLX 63.98
About PNF PIMCO New York Municipal Income Fund
PIMCO New York Municipal Income Fund is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund's portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.